Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Crizotinib by Pfizer for Glioblastoma Multiforme (GBM): Likelihood of Approval
Crizotinib is under clinical development by Pfizer and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Crizotinib by Pfizer for Hepatocellular Carcinoma: Likelihood of Approval
Crizotinib is under clinical development by Pfizer and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...
Crizotinib by Pfizer for Refractory Multiple Myeloma: Likelihood of Approval
Crizotinib is under clinical development by Pfizer and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase...
Crizotinib by Pfizer for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Crizotinib is under clinical development by Pfizer and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
Crizotinib by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Crizotinib is under clinical development by Pfizer and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
Crizotinib by Pfizer for Uveal Melanoma: Likelihood of Approval
Crizotinib is under clinical development by Pfizer and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II...